Skip to content

Tarsus Pharmaceuticals, Inc. TARS Net Investment in Lease

Net Investment in Lease at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
HRO
HarrowHROW
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Warby Parker logo
Warby ParkerWRBY
Glaukos logo
GlaukosGKOS
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s net investment in lease?
Tarsus Pharmaceuticals, Inc. (TARS) reported net investment in lease of $9.99M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s net investment in lease changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s net investment in lease increased by 2443.0% year-over-year, from $393K to $9.99M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s net investment in lease has grown at a 71.1% compound annual growth rate (CAGR), from $688K to $10.08M.